“PSMA scanning is definitely a game-changer with regard to imaging in advanced prostate cancer in urology,” says Evan R. Goldfischer, MD.
In this interview, Evan R. Goldfischer, MD, MBA, FACS, discusses the value of PSMA-PET imaging in prostate cancer. Goldfischer chaired a discussion on the rapidly emeging modalitiy during the 2022 LUGPA Annual Meeting in Chicago, Illinois. Goldfischer is the director of the Research Department at Premier Medical Group in Poughkeepsie, New York, and new LUGPA president.
Analysis underscores value of piflufolastat F 18 in recurrent prostate cancer with low PSA levels
February 23rd 2023The data come from a sub-analysis of the pivotal phase 3 CONDOR trial of the PSMA-targeted radiopharmaceutical piflufolastat F 18 in men with suspected recurrence of prostate cancer.
2 Clarke Drive
Cranbury, NJ 08512